Similarly, in NSCLC, CAR T-cell therapy is being developed to target tumor-specific antigens, such as GPC3, PD-L1, and CD80/CD86, aiming to bypass resistance mechanisms and improve patient outcomes [10]. This evidence concerns the gene CD86 and neoplasm.